BN Business News
Add your company to Business Communicator →

Business · 13/04/2022Updated: 10/17/2026 · 1 min read

Secura Bio, Inc. Seeks FDA Withdrawal of COPIKTRA Approval for Relapsed or Refractory Follicular Lymphoma

Summary

The FDA is withdrawing approval of COPIKTRA (duvelisib) for treating relapsed or refractory follicular lymphoma, following Secura Bio, Inc.'s voluntary request, which waives its right to a hearing

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →